{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:27Z","timestamp":1772165667015,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["10430072010007"],"award-info":[{"award-number":["10430072010007"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressants (ISPs) may have impaired long-term humoral immune responses and increased disease activity after SARS-CoV-2 infection. We aimed to investigate long-term humoral immune responses against SARS-CoV-2 and increased disease activity after a primary SARS-CoV-2 infection in unvaccinated IMID patients on ISPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>IMID patients on active treatment with ISPs and controls (i.e. IMID patients not on ISP and healthy controls) with a confirmed SARS-CoV-2 infection before first vaccination were included from an ongoing prospective cohort study (T2B! study). Clinical data on infections and increased disease activity were registered using electronic surveys and health records. A serum sample was collected before first vaccination to measure SARS-CoV-2 anti-receptor-binding domain (RBD) antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 193 IMID patients on ISP and 113 controls were included. Serum samples from 185 participants were available, with a median time of 173\u00a0days between infection and sample collection. The rate of seropositive IMID patients on ISPs was 78% compared to 100% in controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Seropositivity rates were lowest in patients on anti-CD20 (40.0%) and anti-tumor necrosis factor (TNF) agents (60.5%), as compared to other ISPs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively). Increased disease activity after infection was reported by 68 of 260 patients (26.2%; 95% CI 21.2\u201331.8%), leading to ISP intensification in 6 out of these 68 patients (8.8%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IMID patients using ISPs showed reduced long-term humoral immune responses after primary SARS-CoV-2 infection, which was mainly attributed to treatment with anti-CD20 and anti-TNF agents. Increased disease activity after SARS-CoV-2 infection was reported commonly, but was mostly mild.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>NL74974.018.20, Trial ID: NL8900. Registered on 9 September 2020.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08298-6","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:06:12Z","timestamp":1684296372000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity"],"prefix":"10.1186","volume":"23","author":[{"given":"Koos P. J.","family":"van Dam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriaan G.","family":"Volkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen W.","family":"Stalman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Y. L.","family":"Kummer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zo\u00e9 L. E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander W.","family":"Tas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Boekel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit J.","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneke J.","family":"van der Kooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Bart","family":"Takkenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert R. A. M.","family":"D\u2019Haens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis I.","family":"Spuls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel W.","family":"Bekkenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelie H.","family":"Musters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoline F.","family":"Post","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela L.","family":"Bosma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc L.","family":"Hilhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosta","family":"Vegting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederike J.","family":"Bemelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre E.","family":"Voskuyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Broens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agner Parra","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile A. C. M.","family":"van Els","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelle","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan J. G. M.","family":"Verschuuren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabel M.","family":"Ruiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte","family":"van Ouwerkerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"van der Woude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9e C. F.","family":"Allaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. K. Onno","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"van Paassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias H.","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Papay B. P.","family":"Jallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Brusse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad\u00e1ja E.","family":"Baars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk Jan","family":"Hijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corine R. G.","family":"Schreurs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Stephan","family":"Goedee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"Steenhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofie","family":"Keijzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim B. D.","family":"Keijser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olvi","family":"Cristianawati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"ten Brinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels J. M.","family":"Verstegen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Marieke","family":"van Ham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"L\u00f6wenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-4364","authenticated-orcid":false,"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the T2B! Immunity against SARS-CoV-2 study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"issue":"6","key":"8298_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41577-021-00550-x","volume":"21","author":"D Cromer","year":"2021","unstructured":"Cromer D, Juno JA, Khoury D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021;21(6):395\u2013404.","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"8298_CR2","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","volume":"386","author":"Y Goldberg","year":"2022","unstructured":"Goldberg Y, Mandel M, Bar-On YM, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med. 2022;386(23):2201\u201312.","journal-title":"N Engl J Med"},{"issue":"5","key":"8298_CR3","doi-asserted-by":"publisher","first-page":"e338","DOI":"10.1016\/S2665-9913(22)00034-0","volume":"4","author":"L Wieske","year":"2022","unstructured":"Wieske L, van Dam KPJ, Steenhuis M, et al. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study. The Lancet Rheumatology. 2022;4(5):e338\u201350.","journal-title":"The Lancet Rheumatology"},{"key":"8298_CR4","doi-asserted-by":"crossref","unstructured":"Boekel L, Hooijberg F, Vogelzang EH, et al. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study. RMD Open. 2022;8(1):e002035.","DOI":"10.1136\/rmdopen-2021-002035"},{"issue":"5","key":"8298_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/gutjnl-2021-324388","volume":"70","author":"NA Kennedy","year":"2021","unstructured":"Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5):865\u201375.","journal-title":"Gut"},{"key":"8298_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103153","volume":"55","author":"S Klineova","year":"2021","unstructured":"Klineova S, Harel A, Straus Farber R, et al. Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC). Mult Scler Relat Disord. 2021;55: 103153.","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"8298_CR7","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jamaneurol.2021.1364","volume":"78","author":"ZLE van Kempen","year":"2021","unstructured":"van Kempen ZLE, Strijbis EMM, Al MMCT, et al. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. JAMA Neurol. 2021;78(7):880\u20132.","journal-title":"JAMA Neurol"},{"key":"8298_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152025","volume":"55","author":"M Di Iorio","year":"2022","unstructured":"Di Iorio M, Cook CE, Vanni KMM, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. Semin Arthritis Rheum. 2022;55: 152025.","journal-title":"Semin Arthritis Rheum"},{"key":"8298_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155873","volume":"154","author":"L Mobasheri","year":"2022","unstructured":"Mobasheri L, Nasirpour MH, Masoumi E, Azarnaminy AF, Jafari M, Esmaeili S-A. SARS-CoV-2 triggering autoimmune diseases. Cytokine. 2022;154: 155873.","journal-title":"Cytokine"},{"key":"8298_CR10","doi-asserted-by":"publisher","first-page":"102580","DOI":"10.1016\/j.jaut.2020.102580","volume":"117","author":"JC Sarmiento-Monroy","year":"2021","unstructured":"Sarmiento-Monroy JC, Espinosa G, Londo\u00f1o M-C, et al. A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. J Autoimmun. 2021;117:102580.","journal-title":"J Autoimmun"},{"issue":"5","key":"8298_CR11","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/rheumatology\/keab611","volume":"61","author":"T Schioppo","year":"2022","unstructured":"Schioppo T, Argolini LM, Sciascia S, et al. Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology (Oxford). 2022;61(5):1928\u201335.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"8298_CR12","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.1016\/S2665-9913(22)00102-3","volume":"4","author":"L Boekel","year":"2022","unstructured":"Boekel L, Stalman EW, Wieske L, et al. Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies. The Lancet Rheumatology. 2022;4(6):e417\u201329.","journal-title":"The Lancet Rheumatology"},{"key":"8298_CR13","doi-asserted-by":"publisher","first-page":"e77969","DOI":"10.7554\/eLife.77969","volume":"11","author":"NJM Verstegen","year":"2022","unstructured":"Verstegen NJM, Hagen RR, van den Dijssel J, et al. Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273. eLife. 2022;11:e77969.","journal-title":"eLife"},{"issue":"1","key":"8298_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12916-022-02310-7","volume":"20","author":"L Wieske","year":"2022","unstructured":"Wieske L, Kummer LYL, van Dam KPJ, et al. Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases. BMC Med. 2022;20(1):100.","journal-title":"BMC Med"},{"key":"8298_CR15","unstructured":"WHO, Novel Coronavirus. \"COVID-19 therapeutic trial synopsis.\" R&D Blue Print. 2020. https:\/\/www.who.int\/publications\/i\/item\/covid-19-therapeutic-trial-synopsis."},{"issue":"12","key":"8298_CR16","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.4049\/jimmunol.2000767","volume":"205","author":"EH Vogelzang","year":"2020","unstructured":"Vogelzang EH, Loeff FC, Derksen NIL, et al. Development of a SARS-CoV-2 Total Antibody Assay and the Dynamics of Antibody Response over Time in Hospitalized and Nonhospitalized Patients with COVID-19. J Immunol. 2020;205(12):3491\u20139.","journal-title":"J Immunol"},{"issue":"5","key":"8298_CR17","doi-asserted-by":"publisher","first-page":"e1285","DOI":"10.1002\/cti2.1285","volume":"10","author":"M Steenhuis","year":"2021","unstructured":"Steenhuis M, van Mierlo G, Derksen NI, et al. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors. Clin Transl Immunology. 2021;10(5):e1285.","journal-title":"Clin Transl Immunology"},{"key":"8298_CR18","doi-asserted-by":"publisher","first-page":"103014","DOI":"10.1016\/j.msard.2021.103014","volume":"52","author":"WL Conte","year":"2021","unstructured":"Conte WL. Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: A case-control study. Multiple Sclerosis and Related Disorders. 2021;52:103014.","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"3","key":"8298_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/ecco-jcc\/jjab153","volume":"16","author":"N Chanchlani","year":"2022","unstructured":"Chanchlani N, Lin S, Chee D, et al. Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11422 biologic-treated patients. J Crohns Colitis. 2022;16(3):389\u201397.","journal-title":"J Crohns Colitis"},{"issue":"6521","key":"8298_CR20","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1126\/science.abd7728","volume":"370","author":"A Wajnberg","year":"2020","unstructured":"Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227\u201330.","journal-title":"Science"},{"issue":"1","key":"8298_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927","volume":"21","author":"A Jena","year":"2022","unstructured":"Jena A, Mishra S, Deepak P, et al. Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis. Autoimmun Rev. 2022;21(1): 102927.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"8298_CR22","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1002\/jmv.28063","volume":"94","author":"UM Geisen","year":"2022","unstructured":"Geisen UM, Rose R, Neumann F, et al. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNF\u03b1 blockade. J Med Virol. 2022;94(12):5780\u20139.","journal-title":"J Med Virol"},{"issue":"6","key":"8298_CR23","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1016\/S2665-9913(22)00069-8","volume":"4","author":"RH Haberman","year":"2022","unstructured":"Haberman RH, Um S, Axelrad JE, et al. Methotrexate and TNF inhibitors affect long-term immunogenicity to COVID-19 vaccination in patients with immune-mediated inflammatory disease. Lancet Rheumatol. 2022;4(6):e384\u20137.","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"8298_CR24","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1016\/S2665-9913(22)00191-6","volume":"4","author":"D Simon","year":"2022","unstructured":"Simon D, Tascilar K, Fagni F, et al. Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study. Lancet Rheumatol. 2022;4(9):e614\u201325.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"8298_CR25","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1056\/NEJMc2025179","volume":"383","author":"FJ Ibarrondo","year":"2020","unstructured":"Ibarrondo FJ, Fulcher JA, Goodman-Meza D, et al. Rapid Decay of Anti\u2013SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med. 2020;383(11):1085\u20137.","journal-title":"N Engl J Med"},{"issue":"5","key":"8298_CR26","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1681\/ASN.2020111618","volume":"32","author":"H Sakhi","year":"2021","unstructured":"Sakhi H, Dahmane D, Attias P, et al. Kinetics of Anti\u2013SARS-CoV-2 IgG Antibodies in Hemodialysis Patients Six Months after Infection. J Am Soc Nephrol. 2021;32(5):1033\u20136.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"8298_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001687","volume":"7","author":"C Sengler","year":"2021","unstructured":"Sengler C, Eulert S, Minden K, et al. Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany. RMD Open. 2021;7(2): e001687.","journal-title":"RMD Open"},{"issue":"6","key":"8298_CR28","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00415-018-8751-9","volume":"265","author":"NE Gilhus","year":"2018","unstructured":"Gilhus NE, Romi F, Hong Y, Skeie GO. Myasthenia gravis and infectious disease. J Neurol. 2018;265(6):1251\u20138.","journal-title":"J Neurol"},{"issue":"4","key":"8298_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3899\/jrheum.121081","volume":"40","author":"N Zeboulon-Ktorza","year":"2013","unstructured":"Zeboulon-Ktorza N, Boelle PY, Nahal RS, et al. Influence of Environmental Factors on Disease Activity in Spondyloarthritis: A Prospective Cohort Study. J Rheumatol. 2013;40(4):469\u201375.","journal-title":"J Rheumatol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08298-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:08:56Z","timestamp":1684296536000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08298-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8298"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08298-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2272601\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the medical ethical committee, and all participants provided signed informed consent (NL74974.018.20, EudraCT 2021\u2013001102-30, Dutch Trial Register Trial ID: NL8900).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Joep Killestein, has speaking relationships with Merck, Biogen, TEVA, Sanofi, Genzyme, Roche and Novartis. AmsterdamUMC, location VUmc, MS Center Amsterdam has received financial support for research activities from Merck, Celgene, Biogen, GlaxoSmithKline, Immunic, Roche, Teva, Sanofi, Genzyme, and Novartis. Geert D\u2019Haens has been a consultant for AbbVie, Agomab, AstraZeneca, AM Pharma, AMT, Arena Pharmaceuticals, Bristol Meiers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Exeliom Biosciences, Exo Biologics, Galapagos, Index Pharmaceuticals, Kaleido, Roche, Gilead, GlaxoSmithKline, Gossamerbio, Pfizer, Immunic, Johnson & Johnson, Origo, Polpharma, Procise Diagnostics, Prometheus Laboratories, Prometheus Biosciences, Progenity, and Protagonist; and has received speaker\u2019s bureau fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Pfizer, BMS, and Takeda. Phyllis Spuls is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department\/hospital and is one of the main investigator of the TREAT registry taskforce and SECURE-AD registry. Barbara Horv\u00e1th reports fees from Janssen-Cilag (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), AbbVie (Advisory Boards, Educational grants, Consultations, Investigator Initiative Studies), Novartis Pharma (Advisory Boards, Consultations, Investigator Initiative Studies), UCB Pharma (Advisory Boards, Consultations), Leo Pharma (Consultations), Solenne B.V. (Investigator Initiative Studies), Celgene (Consultations, Investigator Initiative Studies), Akari therapeutics (Consultations, Investigator Initiative Studies), Philips (Consultation), Roche (Consultation), Regeneron (Consultation) and Sanofi (Consultation), Argenx (Advisory Boards, Consultations) which fees were paid to the institution. Jan Verschuuren receives financial support from Target to B consortium, Prinses Beatrix Spierfonds, and has been involved in trials or consultancies for Argenx, Alexion, Rapharma. He is coinventor on patent applications based on MuSK-related research. The LUMC received royalties from IBL and Argenx for MG research. All reimbursements were received by the LUMC. The authors are members of the European Reference Network for Rare Neuromuscular Diseases [ERN EURO-NMD]. DirkJan Hijnen is investigator for AbbVie, LEO pharma, MedImmune\/AstraZeneca, Novartis, Sanofi\/Regeneron; consultancies for Regeneron\/Sanofi, LEO pharma, MedImmune\/AstraZeneca, Novartis, Incyte, Janssen, Pfizer. Mark L\u00f6wenberg has served as speaker and\/or principal investigator for: Abbvie, Alimentiv, Bristol Myers Squibb, Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Galapagos, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeutics, Receptos, Takeda, Tillotts, Tramedico. He has received research grants from AbbVie, Merck Sharp & Dohme, Dr Falk, Achmea healthcare, Galapagos and ZonMW. Filip Eftimov reports (governmental) grants from ZonMw (the Netherlands Organization for Health Research and Development) to study immune responses after SARS-CoV-2 vaccination in autoimmune diseases. He also received grants from Prinses Beatrix Spierfonds, CSL Behring, Kedrion, Terumo BCT, Grifols, Takeda Pharmaceutical Company, and Guillain-Barr\u00e9 Syndrome-Chronic Inflammatory Demyelinating Polyneuropathy (GBS-CIDP) Foundation; consulting fees from UCB Pharma and CSl Behring; and honoraria from Grifols. Diane van der Woude has received research grants from Inova diagnostics, FOREUM (Foundation for Research in Rheumatology) and ZonMw (the Netherlands Organization for Health Research and Development), as well as consulting fees from Galapagos. All other authors had no conflicts of interest. The authors\/Several authors of this publication are members of the Netherlands Neuromuscular Center (NL-NMD) and the European Reference Network for rare neuromuscular diseases EURO-NMD.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}